• 제목/요약/키워드: Antiplatelet agent

검색결과 46건 처리시간 0.022초

항혈소판제를 투여받는 환자의 치과치료 (Dental treatment of the patient with antiplatelet agent)

  • 박홍주
    • 대한치과의사협회지
    • /
    • 제57권10호
    • /
    • pp.606-612
    • /
    • 2019
  • Antiplatelet agent is administered to the patients who have ischemic heart disease, transient cerebral infarction, as well as hypertension, etc. Antiplatelet agent prevents thromboembolism by inhibition of platelet aggregation by various mechanism. Due to that reason, patient who administered antiplatelet agent has bleeding tendency. Surgeon does not want to make a complication by bleeding during and after operation, and want to stop taking antiplatelet agent. However, It is very dangerous for the patient to stop antiplatelet agent. Local bleeding as a complication after operation is considered minor one, whereas thromboembolism is life threatening serious complication. Most dental intervention can be performed without withdrawal of antiplatelet agent. Dental intervention should be limited area, and surgeon should do active bleeding control.

  • PDF

술 전 항혈소판제 복합투여가 무심폐기하 관상동맥우회술 후 출혈에 미치는 영향 (Effects of Combined Antiplatelets on Bleeding in Off-Pump Coronary-Artery Bypass Surgery)

  • 이수경;김태진;송윤석;정선호;양경호;최강주;김용복
    • Journal of Yeungnam Medical Science
    • /
    • 제28권2호
    • /
    • pp.124-132
    • /
    • 2011
  • Background: Antiplatelet agent administration is critical in managing coronary-artery disease, but there is a concern regarding operation-related bleeding and an increase in blood transfusion in such, especially when delivering combined antiplatelet agents. This study was conducted to evaluate the effect of the administration of antiplatelet agents on off-pump coronary-artery bypass surgery (OPCAB). Methods: From March 2003 to December 2009, 49 patients who had undergone OPCAB were collected retrospectively. The patients were divided into three groups according to the administration of antiplatelet agents before the OPCAB operation: 21 patients were given an aspirin agent (group 1), 19 patients were given combined agents (aspirin+clopidogrel) (group 2), and nine patients were not given any antiplatelet agent (group 3). The three groups' perioperative hematologic and coagulation profiles, including their platelet counts, hemoglobin levels, hematocrit, prothrombin times, and aPTTs (activated partial thromboplastin times), and their postoperative bleeding, related complications, transfusion requirements, and operation times, were compared. Results: The operation time in group 2 was 4.3 hours, longer than those in the two other groups, and urgent operation was significantly most frequent in group 2 (63%). The amount of blood loss and the number of patients who received blood transfusion were not different in the three groups. The perioperative hemoglobin level, hematocrit, platelet count, prothrombin time, and aPTT were also not significantly different among the three groups. Conclusion: The continuous administration of antiplatelet agents to the patients in this study did not increase their postoperative bleeding or operation-related complications. Therefore, OPCAB may well be considered even if combined antiplatelet agents are being administered.

  • PDF

ANTIPLATELET AND ANTITHROMBOTIC ACTIVITIES OF VK-708, A NEWLY SYNTHESIZED VITAMIN K DERIVATIVE

  • Jin, Yong-Ri;Ryu, Chung-Kyu;Shin, Hwa-Sup;Yun, Yeo-Pyo
    • 한국독성학회:학술대회논문집
    • /
    • 한국독성학회 2002년도 Current Trends in Toxicological Sciences
    • /
    • pp.118-118
    • /
    • 2002
  • It has been reported that vitamin K analogues have various pharmacological effects such as antiviral, antifungal, anticancer, and antiplatelet activities. It has also been reported that some synthetic naphthoquinone compounds showed antiplatelet activities.(omitted)

  • PDF

Evaluation of Bleeding After Denal Extraction in Patients Taking Single Antiplatelet Treatment

  • Kim, Jae Jin;Kim, Hak Kyun
    • International Journal of Oral Biology
    • /
    • 제40권3호
    • /
    • pp.147-150
    • /
    • 2015
  • The purpose of this study was to evaluate the effect of single antiplatelet treatment on delayed bleeding, in patients undergoing dental extraction. A total of 154 teeth were extracted in 94 patients with ongoing antiplatelet treatment, who were taking single antiplatelet of either aspirin or clopidogrel. All patients underwent simple dental extraction; local hemostasis was performed with gauze-biting, suturing, and/or application of a local hemostatic agent. Delayed bleeding was recorded in 5 teeth out of a total of 154 teeth after extraction, the incidence of postoperative delayed bleeding being 3.2%. The bleeding was controlled by the patients themselves, through application of pressure with additional gauze-biting. No one visited the doctor or emergency room for hemostasis. These results confirmed that patients taking single antiplatelet drugs may have teeth extracted safely without interruption of the antiplatelet treatment.

항혈소판제제와 청혈강기탕(淸血降氣湯)을 병용 투여하여 CT영상에서 저음영부위의 감소를 보인 허혈성 뇌혈관질환 환자의 증례 보고 (A Case Report of dcrease of hypodense region on CT images in ischemic cerebrovascular disease patient treated with Antiplatelet agent and Cheonghyulgangki-tang)

  • 신우재;차지혜;김태연;박유진;고흥;김기태;신선미
    • 대한한방내과학회지
    • /
    • 제31권2호
    • /
    • pp.380-387
    • /
    • 2010
  • The ischemic penumbra represents part of the hypoperfused region associated with focal brain ischemia. A practical approach is to define this region as that portion of the ischemic territory that can potentially be salvaged by timely intervention. For the prevention and treatment of ischemic stroke, antithrombotic therapy is prescribed. But medication of antiplatelet agent is only validated as prevention effect. Cheonghyulgangki-tang has been used for cerebral apoplexy, hypertension, etc. In this case report, an acute ischemic stroke patient was treated with an antiplatelet agent named Plavix and Cheonghyulgangki-tang and remarkable reduction of ischemic portion in the brain CT was observed. The result of this case suggests that oriental medical therapy could be a safe and effective intervention in acute ischemic stroke.

Safety of Perioperative Maintenance of Antiplatelet Agents in Elderly Patients Undergoing Lung Cancer Surgery

  • Hee Ju Hong;Ji Hyeon Park;Samina Park;In Kyu Park;Chang Hyun Kang;Young Tae Kim
    • Journal of Chest Surgery
    • /
    • 제57권4호
    • /
    • pp.342-350
    • /
    • 2024
  • Background: The maintenance of antiplatelet therapy increases the risk of bleeding during lung cancer surgery. Conversely, the perioperative interruption of antiplatelet therapy may result in serious thrombotic complications. This study aimed to investigate the safety of continuing antiplatelet therapy in the context of lung cancer surgery. Methods: We retrospectively reviewed a cohort of 498 elderly patients who underwent surgery for lung cancer. These patients were categorized into 2 groups: group N, which did not receive antiplatelet therapy, and group A, which did. Group A was subsequently subdivided into group Am, where antiplatelet therapy was maintained, and group Ai, where antiplatelet therapy was interrupted. We compared the incidence of bleeding-related and thrombotic complications across the 3 groups. Results: There were 387 patients in group N and 101 patients in group A (Ai: 70, Am: 31). No significant differences were found in intraoperative blood loss, thoracotomy conversion rates, transfusion requirements, volume of chest tube drainage, or reoperation rates for bleeding control between groups N and A or between groups Am and Ai. The duration of hospital stay was longer for group A compared to group N (7 days vs. 6 days, p=0.005), but there was no significant difference between groups Ai and Am. The incidence of cardiovascular or cerebrovascular complications did not differ significantly between groups Ai and Am. However, group Ai included a severe case of in-hospital ST-elevation myocardial infarction. Conclusion: The maintenance of antiplatelet therapy was found to be safe in terms of perioperative bleeding and thrombotic complications in elderly lung cancer surgery patients.

대두가수분해물로부터 새로운 항혈전성 펩타이드, SSGE와 DEE의 분리

  • 이경애;김승호
    • 식품기술
    • /
    • 제17권3호
    • /
    • pp.69-74
    • /
    • 2004
  • A soy protein hydrolysate was found to inhibit rat platelet aggregation induced by ADP, an aggregating agent. To find out its principal antiplatelet peptide(s), the soy protein hydrolysate was separated successively by gel filtration chromatography, revere-phase HPLC, and cation exchange HPLC. During the course of separation, we observed that most fractions had antiplatelet effects, which suggests that most peptides have some degree of antiplatelet effect. Following the inhibitory fractions, we purified and identified two new peptides, SSGE and DEE, by LC-electrospray ionization MS and peptide equencing. Both peptides were highly hydrophilic. The concentrations to obtain 50% inhibition ($IC_50$) of the aggregation intensity were approximately $\458muM$ and $\485muM$, respectively, for SSGE and DEE.

  • PDF

아스파라톤에 의한 사이클로옥시게나제의 저해 - in Vitro (In Vitro Inhibition of Cyclooxygenase by Aspalatone)

  • 서대연;한병훈
    • 약학회지
    • /
    • 제39권5호
    • /
    • pp.565-568
    • /
    • 1995
  • A new antiplatelett agent, aspalatone ([3-(2-methyl-4-pyronyl)]-2-acetyloxybenzoate) was demonstrated to inhibit MDA generation from arachidonic acid catalyzed by partially purified bovine seminal vesicle cyclooxygenase. This inhibition was also observed with acetylsalicylic acid. The results suggest that the mechanism for the antiplatelet effect of aspalatone is, like acetylsalicylic acid, due to its inhibition of cyclooxygenase.

  • PDF

허혈성 뇌졸중에서의 항혈전 치료 (Antithrombotic Therapy for Ischemic Stroke)

  • 하정상;이준
    • Journal of Yeungnam Medical Science
    • /
    • 제20권1호
    • /
    • pp.1-12
    • /
    • 2003
  • Ischemic stroke is among the principal causes of death and disability in the elderly. Although control of blood pressure, decreased cigarette smoking, and modified dietary habits are among important reasons for stroke decline, the use of antithrombotic therapy, rigorously prescribed. Several antiplatelet agents are approved to reduce the risk of recurrent stroke. Aspirin is the best-studied and most widely used antiplatelet agent for stroke prevention; it provides approximately 15% to 25% relatively risk reduction for secondary prevention of stroke or the major vascular death. Combining 2 antiplatelet agents with different mechanism of action was demonstrated to provide a substantial increase in efficacy in several studies. Anticoagulation should be considered first with potential cardiac sources of embolism. Heparin reduces development of erythrocyte-fibrin thrombi that form in regions of vascular stasis especially within the heart, in severely stenosed arteries sometimes engrafted on white thrombi, in acute arterial occlusion. Heparin should not be indiscriminately given to all acute brain ischemia patients, but may contribute to treatment of large artery occlusion and severe stenosis, cardiogenic embolism with a high acute recurrence risk, and dural sinus and cerebral venous thromobosis.

  • PDF